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1First-generation drug-eluting stents (DESs) implanta-tion has been associated with increased risk of late 
stent thrombosis (ST) and very late ST.1 A delayed healing 
response with slower strut coverage compared with bare-
metal stents was identified as the main mechanism of late 
ST and very late ST2 leading to the recommendation for pro-
longed duration of dual antiplatelet therapy (DAPT).3 Among 
the drug/polymer/stent platform triad that constitutes a DES, 
the polymer has been the principal culprit of late ST and 
very late ST4 because of the lack of the biocompatibility of 
polymers used in first-generation DES. However, interac-
tion of drug (paclitaxel or sirolimus) on the luminal side of 
strut with endothelial cell proliferation and strut thickness 
can play a role in delayed healing patterns. Development of 
DES with bioabsorbable polymers and abluminal coatings 
has been associated5,6 with a decline in ST risk compared 
with first-generation DES and has led to shorter DAPT rec-
ommendation in the newest guidelines.7
Background—To assess the vessel-healing pattern of Ultimaster drug-eluting stent using optical frequency domain imaging. 
Our hypothesis is that biodegradable polymer-based drug-eluting technology allows complete very early strut coverage.
Methods and Results—The DISCOVERY 1TO3 study (Evaluation With OFDI of Strut Coverage of Terumo New Drug 
Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months) is a prospective, single-arm, multicenter study. A 
total of 60 patients with multivessel disease requiring staged procedure at 1 month were treated with Ultimaster. Optical 
frequency domain imaging was acquired at baseline, 1, 2, and 3 months. The primary end point is optical frequency 
domain imaging–assessed strut coverage at 3 months. Mean age of patients was 67.2±9.9 years, and 73.3% were male, and 
36.7% presented with acute coronary syndrome. A total of 132 lesions were treated, with average 1.4 lesions per patient 
treated at baseline and 1.1 lesions treated at 1 month. Strut coverage at 3 months of single implanted stents (n=71, primary 
end point) was 95.2±5.2% and of combined single and overlapped stents was 95.4±4.9%. Strut coverage of combined 
single and overlapped stents at 1 (n=49) and 2 months (n=38) was 85.1±12.7% and 87.9±10.8%, respectively. The median 
neointimal hyperplasia thickness was 0.04, 0.05, and 0.06 mm, whereas mean neointimal hyperplasia obstruction was 
4.5±2.4%, 5.2±3.4%, and 6.6±3.3% at 1, 2, and 3 months, respectively.
Conclusions—Nearly complete strut coverage was observed in this complex population very early after implantation of 
Ultimaster drug-eluting stent.
Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT01844843.   
(Circ Cardiovasc Interv. 2017;10:e004801. DOI: 10.1161/CIRCINTERVENTIONS.116.004801.)
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2  Chevalier et al  The DISCOVERY 1TO3 Study
The recent development of light-based intravascular imag-
ing with the improved resolution of optical frequency domain 
imaging (OFDI) was associated with increased capability to 
evaluate both acute stent implantation results8 and late healing 
process including late malapposition,9 vessel remodeling, and 
strut coverage.10,11 OFDI has thus emerged as excellent tool to 
evaluate the time course of strut coverage.
Development of a new reduced dose sirolimus-eluting 
stent using a gradient abluminal bioabsorbable coating pro-
cess on a thin-strut platform (Ultimaster; Terumo, Tokyo, 
Japan) has a potential to obtain a different strut coverage than 
early generation of bioabsorbable polymer-based DES.12–14 
The objective of our study is to assess the vessel-healing pat-
tern of Ultimaster DES using OFDI.
Methods
The data, analytic methods, and study materials will not be made 
available to other researchers for purposes of reproducing the results 
or replicating the procedure.
Study Design
The DISCOVERY 1TO3 study (Evaluation With OFDI of Strut 
Coverage of Terumo New Drug Eluting Stent With Biodegradable 
Polymer at 1, 2, and 3 Months) is a prospective, single-arm, multi-
center, open-label study conducted at 5 European sites. The trial was 
sponsored by Terumo Europe. The sponsor approved the trial protocol, 
which was developed by the steering committee, and main outline is 
available in the Data Supplement. The sponsor had no role in analysis 
and interpretation of the data. The ethics committees at each site and 
competent authorities of all participating countries approved the study. 
All patients signed informed consent approved by ethics committees.
Study Stent
The Ultimaster coronary stent has been described in details in previ-
ous reports.12 The study device is a cobalt-chromium bare-metal stent 
(platform) with thin struts (80 μm) coated with sirolimus (3.9 µg/mm 
stent length) in a bioresorbable, Poly (DLlactide-co-caprolactone) 
polymer (PDLLA/PCL=90/10) matrix. The thin biocompatible, 
bioresorbable gradient coating was chosen to optimize performance 
with minimal drug and polymer content and controlled drug release 
kinetics. A reduced drug dose was possible because of an ablumi-
nal coating, which ensures an equal amount of drug delivered to the 
target tissue. Furthermore, coating only the abluminal surface leaves 
the luminal side of the stent free from drug and polymer. Within 3 to 
4 months, the polymer is fully metabolized, and the full dose of the 
drug is released.
Study Population
A total of 60 complex patients with multivessel disease, requiring 
staged procedure at 1 month and agreeing to undergo an invasive fol-
low-up at 3 months, were treated with the Ultimaster stent. OFDI im-
aging was acquired at baseline, 1, 2, and 3 months, and analysis was 
performed by independent core laboratories (Figure 1). Details of the 
design and study schedule are provided in the Data Supplement.
The main inclusion criterion is patients with multivessel disease 
requiring staged procedure within 1 month after baseline (with excep-
tion of Germany where staged procedure was allowed at 3 months to 
comply with regulatory requirements). The main exclusion criteria 
are patients with ST-segment–elevation myocardial infarction, car-
diogenic shock, renal failure (GFR<45 mL/min), left main stenosis 
>50%, heavily calcified lesions, bifurcations requiring 2 stents, and 
aorto-ostial lesions. The complete major inclusion/exclusion criteria 
for the trial are reported in the Data Supplement.
OFDI Procedure and Analysis
The Fastview catheter (Terumo Corp, Tokyo, Japan) was positioned 
distally to the target segment with the tip ≈1.5 cm distal to the region 
of interest. The position of the Fastview catheter was documented by 
cineangiography in an overlap-free, nonforeshortened view of the tar-
get vessel. The automatic injector filled with flash media (ie, contrast or 
mixture with saline) was connected to the standard y-piece of the guid-
ing catheter. After confirming correct position of the Fastview catheter 
by fluoroscopy and that the guiding catheter is selectively engaged into 
the ostium of the coronary artery by fluoroscopy, the artery was cleared 
from blood by automatic injection of flash media at a flow rate of 4 to 5 
mL/s. After sufficient clearance of the artery, the automated pullback was 
started at a speed of 20 mm/s with a frame rate of 160 frames/s. The pull-
back was stopped after visualization of the complete coronary segment. 
OFDI images were acquired with commercially available frequency do-
main system from Lunawave (Terumo Corp). OFDI image analysis was 
performed using a dedicated offline review system by the Core labora-
tory. Stented segments were analyzed by an independent analyst blinded 
to time point after DES implantation. All pullbacks were validated by 
a second analyst. Cross sections with side branches or poor quality of 
OFDI images were excluded from this analysis. Lumen and stent areas 
were drawn in each analyzed cross section, and the derived incomplete 
stent apposition or neointimal hyperplasia areas were calculated as ap-
propriate. The neointimal hyperplasia thickness was determined based 
on automated measurements performed from the center of the luminal 
surface of each strut blooming and its distance to the lumen contour.9 An 
uncovered strut was defined as having a neointimal hyperplasia thickness 
of 0 mm.9 A malapposed strut was defined as a distance between the cen-
ter reflection of the strut and the vessel wall greater than strut thickness 
(bioresorbable polymer sirolimus-eluting stent [BP-SES], 0.80 μm).15
End Points
The primary end point of the DISCOVERY 1TO3 study is OFDI-
assessed percentage of stent strut coverage at 3 months postprocedure 
in single implanted stents, with the hypothesis of <20% uncovered 
stent struts. Secondary end points include strut coverage at 1 and 2 
months, percentage of acquired malapposed struts, neointimal hy-
perplasia thickness and obstruction at 1, 2, or 3 months, and 1-year 
clinical outcomes. DAPT was recommended for minimum 6 months. 
(Detailed end point definitions are given in the Data Supplement.) 
The clinical end points were defined according to the Academic 
Research Consortium.16 Analyses of clinical end points were based 
on events adjudicated by the Clinical Event Committee. Data from 
WHAT IS KNOWN
• Evaluation of strut coverage using light-based intra-
vascular imaging has been proposed as a surrogate 
end point for vessel-healing quantification; however, 
the time course of early (<3 months) strut coverage 
with new generation drug-eluting stent has not yet 
been thoroughly analyzed.
WHAT THE STUDY ADDS
• The original design of the present study confirms 
the ability of optical frequency domain imaging to 
quantify progressive strut coverage, showing almost 
full process at 3 months, with an already high rate of 
coverage at 1 month.
• Current data will serve as a basis for a large random-
ized clinical trial assessing the safety of abbreviated 
antiplatelet therapy in recipients of this drug-eluting 
stent.
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3  Chevalier et al  The DISCOVERY 1TO3 Study
the angiographic and OFDI core laboratories (Centre Europeen De 
Recherche Cardiovasculaire, Massy, France; CRC, Sao Paulo, Brazil) 
were used in the analyses.
Statistical Analyses
Statistical analysis was performed in treated population. Continuous 
data are reported as mean±SD, and categorical variables are reported 
as number and percentage of patients. One sample t test with 95% 
upper confidence limit was performed to test whether the primary 
end point is <20%. Nonparametric tests (Wilcoxon signed-rank test) 
were used for the comparison of continuous variables with dependent 
time relationship. For the primary lesions (postprocedure, 1-month, 
and 3-month follow-up), the mixed-effects model was used for the 
longitudinal analysis of continuous variables considering a gamma 
distribution with logarithmic link function. We used paired t test was 
used for QCA analysis with P<0.05 (2-sided) considered to be statis-
tically significant. All analyses were performed using SAS software, 
version 9.1 (SAS Institute).
Results
A total of 60 patients were randomized. Mean age of patients 
was 67.2±9.9 years, 73.3% were male, 30.0% had a previ-
ous PCI or CABG, 23.3% had diabetes mellitus, 63.3% had 
Figure 1. Study design: 60 patients with 
multivessel disease have been included in 
the study. Staged procedure is scheduled 
at 1 month, and optical frequency domain 
imaging (OFDI) is acquired at baseline, 
1, 2, and 3 months. DES indicates drug-
eluting stent.
Table 1. Baseline Characteristics
Baseline Patient Characteristics
n=60 
Patients*
Age, y (mean±SD) 67.2±9.9
Sex, males (%) 73.3
Diabetes mellitus (%) 23.3
Hypertension (%) 63.3
Dyslipidemia (%) 67.8
Family history of CAD (%) 30.0
Current smoker (%) 13.6
Previous PCI (%) 26.7
Previous CABG (%) 3.3
Previous MI (%) 21.7
Angina status (%)
  Stable patients 56.7
  ACS 36.7
Moderate renal insufficiency GFR or MDRD=45–60), (%) 20.0
Baseline lesion characteristics*
  Vessels diseased 2.2±0.5
  Lesions detected 3.2±1.6
  Lesions treated—baseline 1.4±0.6
  Lesions treated—staged procedure at 1 mo (37 patients) 1.1±0.4
  Total lesions treated 2.1±0.7
  Stents implanted per lesion 1.2±0.4
  Implanted stent length per lesion, mm 22.0±10.9
  Implanted stent length per patient, mm 50.4±21.4
ACS indicates acute coronary syndrome.
*One patient withdrew consent.
Figure 2. Optical frequency domain imaging shows covered 
struts (left) and uncovered struts (right).
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4  Chevalier et al  The DISCOVERY 1TO3 Study
hypertension, and 36.7% of patients presented with acute cor-
onary syndrome (Table 1). The mean number of vessels dis-
eased was 2.2±0.5, and mean number of lesions detected was 
3.2±1.6 per patient. A total of 132 lesions were treated, with 
1.4±0.6 lesions per patient treated at baseline and 1.1±0.4 
lesions per patient treated at 1 month staged procedure, 
amounting to a total implanted stent length of 22.0±10.9 mm 
per lesion and 50.4±21.4 mm per patient (Table 1).
OFDI assessment was performed on 98% of lesions 
with 99% visualization success. Strut coverage at 3 months 
of single implanted stents (n=71), the primary end point of 
the study, was 95.2±5.2%. The combined single and over-
lapped stents showed similar coverage, which at 3 months 
was 95.4±4.9% (Figures 2 and 3). Strut coverage of combined 
single and overlapped stents at 1 (n=49) and 2 months (n=38) 
was 85.1±12.7% and 87.9±10.8%, respectively (Figures 4 
and 5). The median neointimal hyperplasia thickness over 
covered struts was 0.04, 0.05, and 0.06 mm, whereas mean 
neointimal hyperplasia obstruction was 4.5±2.4%, 5.2±3.4%, 
and 6.6±3.3% at 1, 2, and 3 months, respectively (Figure 6). 
The frequency of malapposed struts per lesion over time was 
1.7±2.6%, 1.3±2.2%, and 0.69±1.2% (Table 2). The in-stent 
late lumen loss for the Ultimaster stent was 0.04±0.3 mm at 3 
months of follow-up. Complete angiographic follow-up of all 
lesions is reported in Table 3. A paired lesion analysis in 43 
paired lesions at 0, 1, and 3 months were presented in Table I 
in the Data Supplement.
At 3-month follow-up, there were no deaths, whereas 
there were 3 non–Q-wave myocardial infarctions, 1 target 
lesion revascularization, and 1 target vessel revascularization. 
One patient experienced subacute ST because of a large stent 
malapposition left untreated. One-year clinical follow-up 
showed no occurrence of death with 2 additional target lesion 
revascularization (Table 4).
Discussion
To the best of our knowledge, this study is the first serial intra-
vascular imaging evaluation of strut coverage very early (1–3 
months) after DES implantation. The main findings of our study 
are the following: (1) a high level of strut coverage of the Ulti-
master stent at 1-month OFDI follow-up; (2) an increase between 
1 and 3 months of neointimal area and thickness, leading to a 
favorable strut coverage at 3 months evaluation; (3) a progressive 
reduction of strut malapposition; and (4) a good 1-year safety and 
efficacy profile of the Ultimaster stent in this complex multivessel 
diseased patient group. This study improves our insight into endo-
thelial embedding of metallic DES. Ongoing randomized trials 
will investigate the clinical significance of this unique sequential 
OFDI finding by applying very short duration of DAPT.
Consistency With Previous Ultimaster Study
DISCOVERY 1TO3 shows consistent results with the first-in-
man prospective CENTURY trial on the Ultimaster BP-SES.12 
Angiographic late loss at 6 months was 0.04±0.35 mm in the 
CENTURY trial compared with 0.04±0.30 mm in our study. The 
mean strut coverage assessed by OCT was 96.2% with 1.67±4.02 
malapposed stent struts in the CENTURY Trial at 6 months 
compared with 95.2±5.2% with 0.69±1.24% malapposed stent 
struts in the DISCOVERY 1TO3 at 3 months, respectively.12
The Ultimaster BP-SES has also shown safety and effi-
cacy profiles similar to the randomized CENTURY II trial that 
compared the Ultimaster BP-SES stent with the durable poly-
mer everolimus-eluting stent (DP-EES).13 Although the study 
enrolled patients with complex multivessel disease, the results 
of the DISCOVERY 1TO3 were consistent with the CENTURY 
II results.13 The freedom from target lesion failure at 9 months 
Figure 3. Optical frequency domain 
imaging–assessed percentage of uncov-
ered struts at 3 months postprocedure 
in single implanted stents (primary end 
point) was 4.8%. The primary end point 
was reached (P<0.01) on the null hypoth-
esis that uncovered struts were ≥20%.
Figure 4. Frequency of strut coverage of combined both single 
and overlapped stents at 1, 2, and 3 months.
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5  Chevalier et al  The DISCOVERY 1TO3 Study
with the Ultimaster stent was 95.6% in the CENTURY II trial 
versus 91.7% at 12 months in DISCOVERY 1TO3 trial. Target 
vessel revascularization was 4.5% in the CENTURY II trial ver-
sus 5.1% in the DISCOVERY 1TO3. The ST rate was 0.9% and 
1.7% in CENTURY II and DISCOVERY 1TO3, respectively.13
Strut Coverage in Second-Generation DES
OFDI has gained popularity and is frequently used to study 
pattern of vessel healing after DES implantation and also to 
assess potential underlying mechanisms for adverse events.
In a systematic review of strut coverage of different 
DES assessed by OFDI at 6 months, the first-generation 
sirolimus-eluting Cypher stent and paclitaxel-eluting Taxus 
stent showed 10.86% and 5.49% of uncovered struts, respec-
tively.17 At 9 months, Xience DP-EES had a 3.12% rate of 
uncovered struts.17 The Ultimaster BP-SES stent, ablumi-
nally coated with sirolimus in a dose (3.9 μg/mm) less than 
half of those coated on Cypher stent, achieved similar rates 
of uncovered struts of 3.8% and 4.8% at 6 and 3 months, in 
the CENTURY and DISCOVERY 1TO3, respectively. The 
result achieved with zotarolimus-eluting durable polymer 
(Endeavor Resolute) and DP-EES (Xience) stents showed 
coverage rates of 92.6% and 94.2%, respectively, at 13 
months in the RESOLUTE all-comer trials.15 The BP-SES 
Ultimaster stent achieved similar coverage of 95.2% at a 
remarkably shorter duration of 3 months.
Figure 5. Frequency of strut coverage of 
single stents at 1, 2, and 3 months.
Figure 6. Optical frequency domain imaging (OFDI) efficacy end points show neointimal hyperplasia (NIH) area (left), NIH thickness (mid-
dle), and percentage of obstruction (right).
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6  Chevalier et al  The DISCOVERY 1TO3 Study
Guagliumi et al18 showed similarly a low rate of strut 
malapposition of 1.51% and 1.80% with the benchmark 
Promus DP-EES and Xience DP-EES stents at 6 months, 
respectively. We report the lowest frequency of malapposed 
struts of 0.69% to date at 3 months for a DES. Indeed, the per-
centage of uncovered and malapposed struts was surprisingly 
low at 3 months compared with previous studies.14,19
At 9-month follow-up, an OCT substudy of CENTURY 
II trial showed excellent tissue coverage and apposition of 
both BP-SES and DP-EES.20 Rate of uncovered struts at 9 
months was 1.02% and 2.26%, respectively, with a similar 
rate of malapposed struts of 0.10% and 0.11%, respectively, 
in BP-SES and EES groups.
Incomplete vascular healing characterized by the presence of 
struts not covered by neointima and malapposed struts was found 
more frequent with BP-BES (Nobori) compared with DP-EES 
in 1 substudy of NEXT trial.14 There have been concerns on 
the potential inflammatory response because of the shorter elu-
tion than polymer absorption time of BP-BES. Compared with 
BP-BES, BP-SES has fundamental distinctive features in terms 
of stent alloy (cobalt-chromium versus stainless steel), strut 
thickness (80 versus 120 μm), and drug kinetic release/polymer 
absorption time ratio. These differences are believed to translated 
into the high rate of strut coverage and low malapposition rates 
observed in the present study with the Ultimaster BP-SES stent.
We can ascertain that the unique design of this study using 
a sequential OFDI analysis at 1, 2, and 3 months of treated 
lesions demonstrated that strut coverage of the BP-SES 
Ultimaster stent occurs mainly within the first month with 
minor but significant increase, between 1 and 3 months. 
DISCOVERY 1TO3 study reached its primary end point with 
only 4.8% uncovered struts in both single and multiple stented 
lesions at 3 months, despite the high complexity of patients/
lesions.
Strut Coverage Versus Endothelialization
Preclinical studies have shown that strut coverage evaluated 
by OFDI or OCT can correspond to neointima formation, 
fibrin accumulation, or high rates of active inflammation. 
Although Templin et al11 have shown a fine detection of neo-
intimal coverage using OFDI on animal model and Nakano et 
al21 have found a better detection of strut coverage with OFDI 
than IVUS, the correlation between strut coverage and recov-
ery of endothelial function is still unclear.
Soucy et al22 found a high contribution (86%–96%) of 
endothelial cells to the strut coverage in animal models 
after bare-metal stent and DES implantations, whereas in 
Malle et al,23 a low rate of maturity in neointimal tissue was 
reported. In a short series, Murase et al24 described an associa-
tion between coverage homogeneity and quality of response 
Table 2. OFDI Strut-Level Analysis: Single-Stented Lesions
 
Primary Lesions Staged Lesions
0 mo (n=62 
Lesions)
1 mo (n=41 
Lesions)
3 mo (n=60 
Lesions) P Value*
0 mo (n=29 
Lesions)
2 mo (n=32 
Lesions) P Value
Analyzed stent length, mm 19.5±6.2 19.9±5.6 19.9±5.6 0.12 18.1±5.2 18.6±6.7 0.72
Mean stent area, mm2 6.7±2.1 6.9±2.5 7.0±2.2† 0.03 6.9±2.4 7.2±2.5 0.27
Minimum stent area, mm2 5.5±1.9 5.7±2.2 5.8±2.1† 0.01 5.7±2.2 6.0±2.2 0.01
Mean stent diameter, mm 2.9±0.4 2.9±0.5 2.9±0.5† 0.03 2.9±0.5 3.0±0.5 0.12
Stent volume, mm3 128.0±55.3 135.6±60.3 135.0±60.6† 0.05 117.6±45.8 127.0±67.6 0.51
Mean lumen area, mm2 6.8±2.0 6.9±2.4 6.7±2.3† 0.03 7.1±2.4 7.1±2.5 0.15
Minimum lumen area, mm2 5.5±1.7 5.5±2.2 5.4±2.1† 0.01 5.8±2.1 5.8±2.3 0.46
Mean lumen diameter, mm 2.9±0.4 2.9±0.5 2.9±0.5† 0.03 2.9±0.5 2.9±0.6 0.11
Lumen volume, mm3 129.8±54.7 134.2±59.6 130.2±59.7 0.79 121.1±45.4 125.2±66.7 0.26
Mean NIH area, mm2 … 0.3±0.2 0.4±0.2 0.05‡ … 0.4±0.2 N/A
Mean NIH thickness, μm … 40 [40–50] 60 [50–70] <0.01‡ … 50 [40–70] N/A
Percent NIH obstruction, % … 4.5±2.4 6.6±3.3 0.05 … 5.2±3.4 N/A
Frequency of malapposed struts, % 5.3±5.25 1.67±2.59§ 0.69±1.24†║ <0.01 8.1±8.8 1.3±2.2 <0.01
Frequency of cross sections with >30% 
uncovered struts, %, median [IQR]
… 13.0 [2.0–24.5] 0.00 [0.0–3.4] <0.01‡ … 9.5 [0.0–17.9] N/A
Maximum length of consecutive segments of 
uncovered struts, mm, median [IQR]
… 3.7 [2.0–7.2] 1.4 [1.0–2.2] <0.01‡ … 3.5 [1.8–4.7] N/A
Maximum length of consecutive segments of 
malapposed struts, mm, median [IQR]
1.9 [0.98–3.6] 0.5 [0.0–0.6]§ 0.4 [0.0–0.6] †║ <0.01 2.1 [0.0–1.0] 0.6 [0.0–1.0] <0.01
N/A indicates not applicable; NIH, neointimal hyperplasia; and OFDI, optical frequency domain imaging.
*For the serial comparisons among 0, 1, and 3 months (or any other comparison you want to provide).
†P<0.05 for the comparison of 3 vs 0 months.
‡For the comparison between 1 and 3 months.
§P<0.05 for the comparison between 1 and 0 months.
║P<0.05 for the comparison between 3 and 1 months. by guest on D
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to acetylcholine test. On the contrary, Won et al25 found an 
absence of correlation in a group of 112 patients.
Strut Coverage and DAPT Duration
Human autopsy studies reveal that incomplete healing as evi-
denced by uncovered stent struts is the most powerful predic-
tor of late ST.26 Furthermore, the presence of >30% uncovered 
struts was identified to be highly predictive of ST after DES 
implantation.27
Taniwaki et al28 used OCT to examine 64 patients who devel-
oped very late ST during a median of 5-year follow-up after their 
index procedures. A believed cause for the events was identi-
fied using OCT for 98% of cases, including strut malapposition 
(34.5%) and uncovered struts (12.1%). Moreover, uncovered 
and malapposed struts were more common in the thrombosed 
regions. Guagliumi et al27 also identified uncovered struts as the 
most common OCT correlate of ST. In another study, Kim et 
al29 showed that the uncovered group was more likely to have 
complex lesions, smaller reference vessel and stent diameter, 
longer stent, more use of sirolimus-eluting stents, and less use 
of zotarolimus-eluting stents compared with the covered group. 
Contrary, Murakami et al30 described an absence of correlation 
between neointimal growth and absence of thrombosis.
This debate on the protective effect of homogeneous cover-
age obtained as early as 1 month in DISCOVERY 1TO3 trial 
paves the way to the initiation of an abbreviated DAPT study. 
This will be evaluated by the MASTER DAPT trial which will 
enroll 4300 high bleeding risk patients receiving the Ultimaster 
stent. Post-stent implantation, patients will be randomized to 
receive either guideline-recommended standard DAPT treat-
ment or transitioned to APT monotherapy, following 1 month 
of postprocedure DAPT treatment for all patients.
Limitations
There are several limitations in the present study. First, this 
study included a small study population in a prospective and 
nonrandomized study. Therefore, selection bias may exist in 
the present study which might have biased the conclusion. Sec-
ond, the trial was powered for the OFDI end point and as such, 
because of a small number of patients, does not allow the draw-
ing of any conclusions on clinical outcomes. Although strut 
coverage could guide DAPT therapy duration, little is known 
about the correlation between minimal percentage strut cov-
erage, the quality of the coverage tissues, and optimal DAPT 
duration, and whether this can influence clinical outcome with-
out conducting a randomized study addressing the issue.
Conclusions
In this complex patient population, our study demonstrates 
rapid strut coverage of the Ultimaster DES, with the majority 
Table 3.  QCA Analysis in All Lesions
Group 1–3 mo, Primary
Pre Post 1 mo 3 mo P Value
n=80 n=80 n=52 n=68 1 vs 3 mo
RVD (in lesion/in stent), mm 2.5±0.5 2.81±0.46 2.78±0.44 2.83±0.46 0.04
Lesion length, mm 14.3±6.9 … … … …
DS (lesion/in stent), % 70±13 11±6 11±6 13±7 NS
MLD (in stent), mm 0.7±0.3 2.5±0.4 2.5±0.4 2.5±0.4 NS
Acute gain (in stent), mm … 1.8±0.5 … … …
Late loss (in stent), mm … … 0.07±0.3 0.04±0.3 NS
Late loss (in segment), mm … … 0.01±0.5 0.04±0.4 NS
 Pre Post 2 mo  P Value
 n=44 n=44 n=41  post vs 2 m
RVD (in lesion/in stent), mm 2.5±0.5 2.8±0.6 2.8±0.5  NS
Lesion length, mm 13.6±7.1 … …  …
DS (lesion/in stent), % 58±15 11±6 13±6  0.04
MLD (in stent), mm 1.1±0.5 2.5±0.4 2.5±0.5  NS
Acute gain (in stent), mm … 1.4±0.5 …  …
Late loss (in stent), mm … … 0.02±0.3  …
Late loss (in segment), mm … … −0.09±0.4  …
Table 4. Clinical Outcomes
 1 mo 1–3 mo 3 mo to 1 y
Death, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
MI, n (%) 3 (5.1) 0 (0.0) 0 (0.0)
TLR, n (%) 1 (1.7) 0 (0.0) 2 (3.4)
TVR, non-TLR, n (%) 1 (1.7) 0 (0.0) 0 (0.0)
Non-TVR, n (%) 1 (1.7) 0 (0.0) 0 (0.0)
TLF, n (%) 3 (5.1) 0 (0.0) 2 (3.4)
ST, n (%)* 1 (1.7) 0 (0.0) 0 (0.0)
MI indicates myocardial infarction; ST, stent thrombosis; TLF, target 
lesion failure; TLR, target lesion revascularization; and TVR, target vessel 
revascularization.
*ST subacute followed by MI because of large untreated stent malapposition.
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of strut coverage process taking place within the first month 
after stent implantation. The unique sequential OFDI analysis 
at 1, 2, and 3 months of treated lesions improves our insight 
into the embedding of novel metallic BP-DES and paves the 
way for a large-scale randomized trial assessing its clinical 
relevance.
Sources of Funding
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SUPPLEMENTAL MATERIALS 
 
 
Serial assessment of strut coverage of biodegradable polymer DES at one, two and three months after stent implantation by 
optical frequency domain imaging: The DISCOVERY 1TO3 study 
 
Expanded Methods: outline of study protocol 
 
The primary purpose of the DISCOVERY1TO3 study is Optical Frequency Domain Imaging (OFDI) investigation of strut coverage of the sirolimus-
eluting stent with biodegradable polymer at 1, 2 and 3 months after stent implantation. This study is the pilot study to assess feasibility of 
shorter dual antiplatelet therapy (DAPT) after PCI with this new stent. 
 
Design 
This study is a prospective, single arm, multicenter, open label study with adaptive design. All patients will undergo angiographic follow-up at 3 
months, OFDI imaging after baseline and at 1, 2 and 3 months, and clinical follow-up at 1 year. 
The primary endpoint is OFDI assessed percent stent strut coverage at 3 months post procedure. 
Our hypothesis is that less than 20% uncovered struts at 3 months post procedure. The primary endpoint will be assessed for all single stent lesions.  
 
Secondary endpoints include: 
 
1. Number (%) of stent strut coverage at 1 and 2 months; 
2. Number (%) of stented lesions which have >10 % uncovered stent struts at 1, 2 or 3 months; 
3. Number (%) of stented lesions which have >20% uncovered struts at 1, 2 or 3 months; 
4. Percentage of acquired malapposed struts at 1, 2 and 3 months; 
5. Amount of in-stent intimal hyperplasia (mm3) at 1, 2 and 3 months; 
6. Amount of in-segment intimal hyperplasia (mm3) at 1, 2 and 3 months; 
7. Neo-intimal thickness (μm) at 3 months; 
8. In-stent late-lumen loss at 3 months by QCA; 
9. In-segment late lumen loss at 3 months by QCA; 
10. Target Lesion Revascularization (TLR) at 1, 3, and 12 months post-procedure; 
11. Target Vessel Revascularization (TVR) at 1, 3 and 12 months post-procedure; 
12. Target Lesion Failure (TLF), composite endpoint of Cardiac Death, target vessel related 
Myocardial infarction (MI) and Clinically Indicated TLR at 1, 3 and 12 months postprocedure; 
13. Major Cardiac Adverse Events (MACE) defined as cardiac death, MI (Q wave and non-Q 
wave), emergent coronary artery bypass surgery, or target vessel revascularization (TVR) 
at 1, 3 and 12 months post-procedure; 
14. Stent thrombosis at 1, 3 and 12 months post-procedure; 
NOTE: all secondary endpoints will be assessed for single stent lesions and overlapping stent lesions. 
 
Study population 
The study plans to enroll up to 60 patients with coronary multi-vessel disease, clinically indicated as candidates for staged multi-vessel PCI treatment 
of de novo lesions located in native coronary arteries. Number of patients will be decided by number of target lesions treated with single stent, 
assessable at 3 months follow-up, taking into account a 15% drop-out rate. Enrolment will be done in consecutive cohorts of 10 patients. Assessment 
of available lesions suitable for assessment at 3 months will be done per enrolment of patient cohort of 10 patients. Clinical sites are the following: 
Maasstad Ziekenhuis, Rotterdam; Erasmus MC, Rotterdam, MC Leeuwarden, Leeuwarden, the Netherlands; Institut Cardiovasculaire Paris Sud, 
Massy; CHU Rangueil, Toulouse. France; LMU München, Munich, Germany. 
 
Inclusion Criteria are the following: 
1. Patient is at least 18 years old; 
2. Patients is a suitable candidate for PCI; 
3. Patient has multi-vessel disease with ≥2 de-novo lesions in native coronary arteries suitable 
for treatment with TCD-10023 DES; 
4. Target lesions are suitable for OFDI examination; 
5. Patient requires staged procedure between 3-5 weeks after baseline procedure, according 
to investigator’s judgement; 
6. Target vessel reference diameter is between 2.5 - 4.0 mm (visual assessment); 
7. Patient has provided written informed consent; 
8. Patient is affiliated to social security or equivalent system (France only). 
Exclusion Criteria 
1. Patient has known allergy to sirolimus, cobalt, chromium, nickel, or contrast agent (that 
cannot be adequately premedicated); 
2. Patient is not a suitable candidate for use of DAPT because of active or recent bleedings or 
for use of vitamin K antagonist, like warfarin, dabigatran, rivaroxaban or acenocoumarol; 
3. Patient is presenting with STEMI at baseline procedure; 
4. Patient has Killip class > 1 at admission; 
5. Patient is in cardiogenic shock; 
6. Patient is a female of childbearing potential; 
7. Patient has life expectancy of less than 1 year; 
8. Patient is expected to undergo major surgery within 3 months; 
9. Patient has Left Main disease ≥ 50%; 
10. Target lesion at bifurcation requiring 2 stents technique; 
11. Target lesions are severely calcified; 
12. Target lesion is aorta-ostially located (within 3 mm of vessel origin); 
13. Patient has renal failure defined as estimated Glomerular Filtration Rate (eGFR) <50 
mL/min/1.73m²; 
14. Target lesions require preparation other than balloon pre-dilatation; 
15. Patient is currently participating in an investigational drug or device study that has not completed 
the primary endpoint or that clinically interferes with the current study endpoints; 
16. In the Investigator’s opinion patient has (a) co-morbid condition(s) that could limit the patient’s 
ability to participate in the study, compliance with follow-up requirements or impact 
the scientific integrity of the study; 
17. Patient is under judicial protection (France only). 
 
Procedure 
All potential patients must be consented prior to performing any study specific procedures. This study will utilize unique patient numbers for the 
purpose of trial data collection. The Case Report Form (CRF) will be electronic (eCRF) and a unique patient number will be automatically assigned. 
This study is performed as ‘open label’ study, no blinding will be applied. In baseline procedure, pre-dilatation can be performed at discretion of the 
investigator. More than one study stent can be used for elective treatment of a target lesion. Only study stents can be used. 
Post dilatation is not mandatory and left at the discretion of the operator. If a satisfactory result has been obtained (<20% rest stenosis), OFDI 
procedure of the treated segments is done for control and images stored on hard disk. Staged procedures for treatment of multi vessel coronary 
artery disease are planned at 3-5 weeks post index procedure. A staged procedure should be electively planned at the end of the baseline procedure. 
Care should be taken to use only the study stent for treatment of all lesions. Patients will be receiving dual antiplatelet therapy until at 
least 6 months after the last Ultimaster stent implantation. 
 
Follow-up 
Enrolled patients will be followed for a period of 12 months after the index procedure. 
Follow-up procedures for this study will include: 
Assessment of available documentation of referring physicians, including general practitioners as well as cardiologists and family members. 
Any change of medication since last contact should be documented in the eCRF including reason for change. Any suspension or interruption of 
DAPT (ASA, clopidogrel and/or prasugrel or other antiplatelet drug) should be documented in the patient’s records and the case report forms. 
ECG if available. 
A clinical assessment will include: 
Angina status after procedure before discharge. 
All adverse events (serious and non-serious) occurring since procedure. 
Concomitant medications. 
Follow up is scheduled at 3-months post-procedure (±14 days) and 12 months (±30 days). 3 months follow up will include clinical follow up with 
hospital (site) visit and angiographic & OFDI follow up. 12 months follow up will be hospital visit or telephone contact. If in-between protocol 
required visits/telephone contacts, the site study team learns of any adverse events, the available relevant information should be captured on the 
appropriate eCRF page. 
 
Clinical events and reporting 
In this study, patients should be encouraged to report AEs spontaneously or in response to general, non-directed questioning. If it is determined that 
an AE has occurred, the Investigator should obtain all the information required to complete the AE page of the eCRF. In addition, patients will be 
instructed to contact the Investigator, and/or study coordinator if any adverse events occur between study evaluation visits. The Investigator will record 
the nature, severity, treatment and outcome of the AE, and will determine the relationship to the investigational 
products, study mandated medications or any CIP mandated procedures involved in the clinical study. 
 
 
  
 
SUPPLEMENTAL MATERIAL 
 
Data Supplement Table 1: OFDI paired lesion analysis (n=43 pairs)  
 0-Month  1-Month  3-Month  P-Value*  
Analyzed stent length, mm  24.5 ± 12.8  23.8 ± 11.8  24.6 ± 14.0    0.16  
Mean stent area, mm2  7.11 ± 2.58  7.24 ± 2.64  7.19 ± 2.51  <0.01  
Min. stent area, mm2 5.8 ± 2.3  5.92 ± 2.36  5.93 ± 2.32  <0.01  
Mean stent diameter, mm 2.96 ± 0.53  2.98 ± 0.54  2.98 ± 0.51    0.01  
Stent volume, mm3 169.1 ± 102.6  170.6 ± 110.8  169.8 ± 104.6    0.09  
Mean lumen area, mm2 7.22 ± 2.51  7.14 ± 2.58  6.98 ± 2.49  <0.01  
Min. lumen area, mm2 5.8 ± 2.16 5.71 ± 2.32  5.43 ± 2.31  <0.01  
Mean lumen diameter, mm 2.99 ± 0.51  2.96 ± 0.53  2.93 ± 0.51  <0.01  
Lumen volume, mm3 172 ± 103.89  168.53 ± 108.9  163.7 ± 97.2  0.49  
Mean NIH area, mm2 -  0.34 ± 0.19  0.43 ± 0.3  <0.017  
Mean NIH thickness, μm   40  60  <0.01  
Percent NIH obstruction, % -  4.76 ± 2.42  6.08 ± 3.34  <0.01  
Frequency of malapposed struts, %  5.75 ± 5.59  1.79 ± 2.65  1.79 ± 2.65  <0.01  
Frequency of cross-sections 
with>30% uncovered struts, %, 
median [IQR]  
-  12.1 [1.7 – 24.6]  0 [0 – 3.8]  <0.01  
Maximum length of consecutive 
segments of uncovered struts, mm, 
median [IQR] 
-  4.6 [2.1 - 7.4]  1.9 [1.1 - 2.7]  <0.01  
 
 
 
 
ANGIOGRAPHIC CORELAB: CERC, Massy, France 
OFDI: CRC, Sao Paulo, Brazil – Dr Daniel Chamié 
  
Members of the Clinical Events Committee 
 
 
 Name Hospital  Country 
Prof. Dr. Claude Hanet (Chairperson) 
  
UCL CHU de Mont Godinne, 
Avenue Docteur Gaston Therasse 1 
5530 Yvoir 
  
Belgium 
Prof. Dr. Med. Achim Vogt, FESC 
  
Praxis für Kardiologie, Pneumologie und 
Angiologie 
Aachener Straße 327 
D-50931 Köln (Lindenthal) 
  
Germany 
Dr. Jeroen Vos 
  
Amphia Ziekenhuis breda 
Kamer NWO-203 
Research Interventiecardiologie 
Molengracht 21 
4818 CK Breda 
  
Netherlands 
